Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science

Key Takeaways

• First-in-human clinical trial demonstrates favorable safety, tolerability, and device performance for Everads’ suprachoroidal injector
• Thermal imaging visualization confirms posteriorly directed drug distribution in retinal tissue, potentially improving treatment precision
• Clinical data published in Ophthalmology Science validates the company’s novel drug delivery approach for retinal diseases

---

Everads Therapy, a clinical-stage biotechnology company, announced May 3, 2026, the publication of positive first-in-human clinical trial data for its suprachoroidal drug delivery device in Ophthalmology Science, the peer-reviewed journal of the American Academy of Ophthalmology.

Clinical Trial Results Show Promise

The published study demonstrates favorable safety and tolerability profiles for Everads’ novel suprachoroidal injector technology. Most significantly, thermal imaging confirmed posteriorly directed drug distribution, indicating the device successfully delivers medications to targeted retinal areas.

This breakthrough addresses a critical challenge in ophthalmology: precisely delivering therapeutic agents to the back of the eye where many retinal diseases occur. Traditional injection methods often result in suboptimal drug distribution and require frequent re-dosing.

Suprachoroidal Delivery Technology Explained

Evereds’ technology targets the suprachoroidal space, a potential cavity between the sclera and choroid layers of the eye. This approach offers several advantages:

• Enhanced drug distribution to posterior retinal segments
• Reduced systemic exposure compared to intravitreal injections
• Potentially longer duration of therapeutic effect
• Minimized injection-related complications

Market Impact and Future Implications

The retinal disease treatment market, valued at over $12 billion globally, relies heavily on frequent intravitreal injections. Everads’ technology could transform treatment paradigms for conditions including:

• Age-related macular degeneration (AMD)
• Diabetic retinopathy
• Retinal vein occlusion
• Uveitis

ARVO 2026 Presentations

Alongside the publication, Everads will present three studies at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting, providing additional clinical insights and expanding the scientific community’s understanding of suprachoroidal delivery.

The company’s clinical-stage development program positions it to potentially capture significant market share in the rapidly growing retinal therapeutics sector, particularly as an increasing aging population drives demand for innovative treatment options.

---

Frequently Asked Questions

What does this mean for patients with retinal diseases?

This technology could potentially reduce injection frequency and improve drug delivery precision for retinal conditions, though the device still requires further clinical testing before becoming available to patients.

When will Everads’ suprachoroidal injector be available?

The device is still in clinical development following first-in-human trials. Additional Phase 2 and Phase 3 studies will be needed before potential regulatory approval and commercial availability.

How does suprachoroidal delivery compare to current eye injections?

Suprachoroidal delivery targets a different eye compartment than traditional intravitreal injections, potentially offering better drug distribution to the back of the eye with reduced systemic exposure and fewer side effects.